{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:56:08Z","timestamp":1762458968278},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,6,3]],"date-time":"2012-06-03T00:00:00Z","timestamp":1338681600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s12185-012-1101-2","type":"journal-article","created":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T22:53:51Z","timestamp":1338591231000},"page":"74-83","source":"Crossref","is-referenced-by-count":7,"title":["Phase II study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low\u2013intermediate risk, aggressive non-Hodgkin\u2019s lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508"],"prefix":"10.1007","volume":"96","author":[{"name":"The members of the Lymphoma Study Group of the Japan Clinical Oncology Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitoyo","family":"Kagami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kuniaki","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensei","family":"Tobinai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruhiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Mukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Mikuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyasu","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Kiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayo","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuneo","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Tsukasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomitsu","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Shimoyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michinori","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,6,3]]},"reference":[{"issue":"4","key":"1101_CR1","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","volume":"38","author":"EM McKelvey","year":"1976","unstructured":"McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38(4):1484\u201393.","journal-title":"Cancer"},{"issue":"5","key":"1101_CR2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.7326\/0003-4819-102-5-596","volume":"102","author":"P Klimo","year":"1985","unstructured":"Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. Ann Intern Med. 1985;102(5):596\u2013602.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1101_CR3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.7326\/0003-4819-104-6-757","volume":"104","author":"MA Shipp","year":"1986","unstructured":"Shipp MA, Harrington DP, Klatt MM, Jochelson MS, Pinkus GS, Marshall JL, et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med. 1986;104(6):757\u201365.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1101_CR4","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1200\/JCO.1989.7.8.1018","volume":"7","author":"B Coiffier","year":"1989","unstructured":"Coiffier B, Gisselbrecht C, Herbrecht R, Tilly H, Bosly A, Brousse N. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol. 1989;7(8):1018\u201326.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1101_CR5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.1991.9.1.25","volume":"9","author":"DL Longo","year":"1991","unstructured":"Longo DL, DeVita VT Jr. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol. 1991;9(1):25\u201338.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1101_CR6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1532\/IJH97.04085","volume":"80","author":"T Kinoshita","year":"2004","unstructured":"Kinoshita T, Hotta T, Tobinai K, Kobayashi T, Ishizuka N, Tomonaga M, et al. A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin\u2019s lymphoma: Japan Clinical Oncology Group Study 9002. Int J Hematol. 2004;80(4):341\u201350.","journal-title":"Int J Hematol"},{"issue":"14","key":"1101_CR7","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;328(14):1002\u20136.","journal-title":"N Engl J Med"},{"issue":"14","key":"1101_CR8","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","year":"1993","unstructured":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma. The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987\u201394.","journal-title":"N Engl J Med"},{"issue":"9","key":"1101_CR9","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/annonc\/mdf287","volume":"13","author":"K Itoh","year":"2002","unstructured":"Itoh K, Ohtsu T, Fukuda H, Sasaki Y, Ogura M, Morishima Y, et al. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin\u2019s lymphoma: Japan Clinical Oncology Group Study 9505. Ann Oncol. 2002;13(9):1347\u201355.","journal-title":"Ann Oncol"},{"issue":"2","key":"1101_CR10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1093\/jjco\/hyg013","volume":"33","author":"K Takeyama","year":"2003","unstructured":"Takeyama K, Ogura M, Morishima Y, Kasai M, Kiyama Y, Ohnishi K, et al. A dose-finding study of glycosylated G-CSF (lenograstim) combined with CHOP therapy for stem cell mobilization in patients with non-Hodgkin\u2019s lymphoma. Jpn J Clin Oncol. 2003;33(2):78\u201385.","journal-title":"Jpn J Clin Oncol"},{"issue":"10","key":"1101_CR11","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1097-0142(19820515)49:10<2112::AID-CNCR2820491024>3.0.CO;2-2","volume":"49","author":"National Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas","year":"1982","unstructured":"National Cancer Institute sponsored study of classifications of non-Hodgkin\u2019s lymphomas. Summary and description of a working formulation for clinical usage. The Non-Hodgkin\u2019s Lymphoma Pathologic Classification Project. Cancer. 1982;49(10):2112\u201335.","journal-title":"Cancer"},{"issue":"11","key":"1101_CR12","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin\u2019s disease staging classification. Cancer Res. 1971;31(11):1860\u20131.","journal-title":"Cancer Res"},{"issue":"11","key":"1101_CR13","first-page":"1862","volume":"31","author":"SA Rosenberg","year":"1971","unstructured":"Rosenberg SA, Boiron M, DeVita VT Jr, Johnson RE, Lee BJ, Ultmann JE, et al. Report of the committee on Hodgkin\u2019s disease staging procedures. Cancer Res. 1971;31(11):1862\u20133.","journal-title":"Cancer Res"},{"issue":"11","key":"1101_CR14","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","volume":"7","author":"TA Lister","year":"1989","unstructured":"Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin\u2019s disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630\u20136.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1101_CR15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"12","key":"1101_CR16","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","volume":"17","author":"NL Harris","year":"1999","unstructured":"Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835\u201349.","journal-title":"J Clin Oncol"},{"key":"1101_CR17","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, 3 edn. Lyon: IARC Press; 2001."},{"key":"1101_CR18","unstructured":"WHO Handbook for Reporting Results of Cancer Treatment. 1979"},{"issue":"4","key":"1101_CR19","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/oxfordjournals.jjco.a039642","volume":"23","author":"K Tobinai","year":"1993","unstructured":"Tobinai K, Kohno A, Shimada Y, Watanabe T, Tamura T, Takeyama K, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993;23(4):250\u20137.","journal-title":"Jpn J Clin Oncol"},{"key":"1101_CR20","first-page":"378","volume":"13","author":"K Tobinai","year":"1994","unstructured":"Tobinai K, Shimoyama M, Minato K. Japan Clinical Oncology Group (JCOG) trial of second-generation \u201cLSG4 protocol\u201d in aggressive lymphoma including ATL: prognostic factors and a predictive model [abstract]. Proc Am Soc Clin Oncol. 1994;13:378.","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"3","key":"1101_CR21","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1182\/blood-2003-06-2094","volume":"104","author":"M Pfreundschuh","year":"2004","unstructured":"Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104(3):626\u201333.","journal-title":"Blood"},{"issue":"23","key":"1101_CR22","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1995;333(23):1540\u20135.","journal-title":"N Engl J Med"},{"issue":"9","key":"1101_CR23","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1023\/A:1008392528248","volume":"10","author":"M Jerkeman","year":"1999","unstructured":"Jerkeman M, Anderson H, Cavallin-Stahl E, Dictor M, Hagberg H, Johnson A, et al. CHOP versus MACOP-B in aggressive lymphoma\u2014a Nordic Lymphoma Group randomised trial. Ann Oncol. 1999;10(9):1079\u201386.","journal-title":"Ann Oncol"},{"issue":"18","key":"1101_CR24","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005;23(18):4117\u201326.","journal-title":"J Clin Oncol"},{"issue":"9","key":"1101_CR25","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/1097-0142(19821101)50:9<1695::AID-CNCR2820500907>3.0.CO;2-H","volume":"50","author":"JO Armitage","year":"1982","unstructured":"Armitage JO, Dick FR, Corder MP, Garneau SC, Platz CE, Slymen DJ. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer. 1982;50(9):1695\u2013702.","journal-title":"Cancer"},{"issue":"10","key":"1101_CR26","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1002\/1097-0142(19930515)71:10<3130::AID-CNCR2820711039>3.0.CO;2-R","volume":"71","author":"H Nakamine","year":"1993","unstructured":"Nakamine H, Bagin RG, Vose JM, Bast MA, Bierman PJ, Armitage JO, et al. Prognostic significance of clinical and pathologic features in diffuse large B-cell lymphoma. Cancer. 1993;71(10):3130\u20137.","journal-title":"Cancer"},{"issue":"12","key":"1101_CR27","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.leukres.2004.04.016","volume":"28","author":"H Kojima","year":"2004","unstructured":"Kojima H, Hasegawa Y, Suzukawa K, Mukai HY, Kaneko S, Kobayashi T, et al. Clinicopathological features and prognostic factors of Japanese patients with \u201cperipheral T-cell lymphoma, unspecified\u201d diagnosed according to the WHO classification. Leuk Res. 2004;28(12):1287\u201392.","journal-title":"Leuk Res"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1101-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-012-1101-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-012-1101-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,29]],"date-time":"2019-06-29T05:34:44Z","timestamp":1561786484000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-012-1101-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,3]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["1101"],"URL":"https:\/\/doi.org\/10.1007\/s12185-012-1101-2","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"type":"print","value":"0925-5710"},{"type":"electronic","value":"1865-3774"}],"subject":[],"published":{"date-parts":[[2012,6,3]]}}}